Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04148937
Title A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung cancer

breast cancer

ovarian cancer

prostate cancer

kidney cancer

melanoma

pancreatic cancer

Therapies

LY3475070

LY3475070 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.